NYSE - Delayed Quote • USD Phreesia, Inc. (PHR) Follow Add holdings Time to buy PHR? 25.40 0.00 (0.00%) At close: May 19 at 4:00:02 PM EDT 25.40 0.00 (0.00%) After hours: May 19 at 5:47:59 PM EDT Time to buy PHR? All News Press Releases SEC Filings 3 of Wall Street’s Favorite Stocks Skating on Thin Ice Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover. TruBridge (TBRG) Lags Q1 Earnings Estimates TruBridge (TBRG) delivered earnings and revenue surprises of -2.70% and 1.51%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock? Phreesia Updates May 28, 2025, Earnings Release Information for Fiscal First Quarter 2026 Results ALL-REMOTE COMPANY/WILMINGTON, Del., May 06, 2025--Phreesia, Inc. will now release its fiscal first quarter 2026 financial results prior to the open of market trading on Wednesday, May 28, 2025. 1 Cash-Heavy Stock with Impressive Fundamentals and 2 to Ignore Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers. Phreesia Sets Release Date for Fiscal First Quarter 2026 Results ALL-REMOTE COMPANY/WILMINGTON, Del., April 29, 2025--Phreesia will release its fiscal first quarter 2026 financial results after the close of market trading on Wednesday, May 28, 2025. Winners And Losers Of Q4: Evolent Health (NYSE:EVH) Vs The Rest Of The Healthcare Technology for Providers Stocks The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Evolent Health (NYSE:EVH) and the rest of the healthcare technology for providers stocks fared in Q4. Unpacking Q4 Earnings: Omnicell (NASDAQ:OMCL) In The Context Of Other Healthcare Technology for Providers Stocks Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Omnicell (NASDAQ:OMCL) and the best and worst performers in the healthcare technology for providers industry. Q4 Earnings Highs And Lows: Premier (NASDAQ:PINC) Vs The Rest Of The Healthcare Technology for Providers Stocks Looking back on healthcare technology for providers stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Premier (NASDAQ:PINC) and its peers. Phreesia, Inc.'s (NYSE:PHR) Profit Outlook Phreesia, Inc. ( NYSE:PHR ) is possibly approaching a major achievement in its business, so we would like to shine some... Healthcare Technology Stocks Q4 In Review: Hims & Hers Health (NYSE:HIMS) Vs Peers Let’s dig into the relative performance of Hims & Hers Health (NYSE:HIMS) and its peers as we unravel the now-completed Q4 healthcare technology earnings season. Q4 Rundown: Astrana Health (NASDAQ:ASTH) Vs Other Healthcare Technology for Providers Stocks Wrapping up Q4 earnings, we look at the numbers and key takeaways for the healthcare technology for providers stocks, including Astrana Health (NASDAQ:ASTH) and its peers. Q4 Earnings Outperformers: Tandem Diabetes (NASDAQ:TNDM) And The Rest Of The Healthcare Technology Stocks Let’s dig into the relative performance of Tandem Diabetes (NASDAQ:TNDM) and its peers as we unravel the now-completed Q4 healthcare technology earnings season. Select Medical, Phreesia, Eli Lilly, Pfizer, and Brink's Shares Are Falling, What You Need To Know A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White House clarified the tariffs on imports from China would add up to 145%, while the baseline 10% tariffs remained in place for most countries. This reminded investors that the global trade environment remained volatile, limiting the potential for sustained market gains. Wall Street Analysts Think Phreesia (PHR) Could Surge 28.02%: Read This Before Placing a Bet The consensus price target hints at a 28% upside potential for Phreesia (PHR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. 1 Healthcare Stock with Exciting Potential and 2 to Ignore Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 9.5%. This drop was worse than the S&P 500’s 2.3% loss. 1 Small-Cap Stock with Solid Fundamentals and 2 to Ignore Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors. Company News for Mar 14, 2025 Companies in The News Are: QBTS, INTC, DG, PHR Exploring Three High Growth Tech Stocks In The US Market Over the last 7 days, the United States market has experienced a decline of 4.1%, yet it has shown resilience with a 6.6% increase over the past year, and earnings are anticipated to grow by 14% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for revenue expansion and innovation despite short-term market fluctuations. Q4 Earnings Review: Healthcare Technology for Providers Stocks Led by Phreesia (NYSE:PHR) Wrapping up Q4 earnings, we look at the numbers and key takeaways for the healthcare technology for providers stocks, including Phreesia (NYSE:PHR) and its peers. Phreesia Named to G2’s List of 2025 Best Healthcare Software Products ALL-REMOTE COMPANY/WILMINGTON, Del., March 13, 2025--Phreesia has been named to G2’s 2025 Best Software Awards in the Best Healthcare Software Products category. Performance Overview Trailing total returns as of 5/19/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) Return PHR S&P 500 (^GSPC) YTD +0.95% +1.39% 1-Year +4.48% +12.45% 3-Year +50.21% +52.88%